This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
RTP004 enhances presynaptic binding and reduces post-injection diffusion of botulinum toxin.
Why it matters
This research represents a breakthrough in drug delivery systems, potentially improving the efficacy of botulinum toxin treatments. The approval of RTP004-containing products could lead to better therapeutic outcomes in clinical settings.
How the study worked
The study discusses the formulation characteristics and pharmacological properties of RTP004 in relation to botulinum toxin.
What this study cannot tell us
The study primarily focuses on the formulation and does not provide extensive clinical trial data on efficacy and safety.
Read the original research
A technology evaluation of the atypical use of a CPP-containing peptide in the formulation and performance of a clinical botulinum toxin product.
Expert opinion on drug delivery, 20(9), 1157-1166
Citation
Dowdy, Steven F; Gallagher, Conor J; Vitarella, Domenico; Brown, Jessica. (2023). A technology evaluation of the atypical use of a CPP-containing peptide in the formulation and performance of a clinical botulinum toxin product.. Expert opinion on drug delivery, 20(9), 1157-1166. https://doi.org/10.1080/17425247.2023.2251399